Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs UBS Group AG Registered Ordinary Shares — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.98 (market cap $31.07B), while UBS Group AG Registered Ordinary Shares trades at $47.68 (market cap $145.08B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 4.7× GE HealthCare Technologies Inc. Common Stock's market cap, and UBS Group AG Registered Ordinary Shares pays the higher dividend (2.33%). Which is the better fit depends on your goals.
| GEHC | UBS | |
|---|---|---|
Market Cap | $31.07B | $145.08B |
Volume | 3,443,020 | 1,613,745 |
Sector | Health | Financials |
52-Week High | $88.16 | $55.72 |
52-Week Low | $59.48 | $36.41 |
Enterprise Value | $39.53B | $304.42B |
Dividend Yield | 0.23% | 2.33% |
Typical Hold Time | — | 3 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
UBS trades at $47.85, showing minimal daily movement with a 0.06% gain. The technical picture is bearish with mixed earnings performance - beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Analyst sentiment leans positive with 55% buy ratings, though the consensus price target of $23.57 sits well below current levels. Recent news highlights UBS's strategic focus on US expansion and ongoing integration challenges.
The outlook remains cautious given the bearish technical signals and valuation concerns. Investment opportunity exists in the company's improving profitability and revenue growth trajectory, but risks include integration challenges from recent acquisitions and exposure to European debt market volatility. The significant gap between current price and analyst targets warrants careful consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
